



25 October 2023

Dr Michael Winlo appointed to dorsaVi Board

Melbourne, Australia, 25 October 2023: dorsaVi (ASX: DVL) (**dorsaVi** or the **Company**) is pleased to announce the appointment of Dr Michael Winlo to dorsaVi's Board of Directors as Non-Executive Director effective 25 October 2023.

Dr Winlo is a distinguished medical professional and entrepreneur with proven leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer and Managing Director of Emyria Limited (ASX:EMD), a clinical drug development company, as well as a Non-Executive Director of Nanoveu Limited (ASX:NVU), a company specialising in protective films and coatings. Dr Winlo also serves as a Director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services.

Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE:PLTR), a world leading data analytics company. dorsaVi looks forward to leveraging Dr Winlo's extensive managerial experience combined with his deep knowledge of the global healthcare landscape to propel dorsaVi's growth strategy.

Dr Winlo holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of Western Australia and a Master of Business Administration (MBA) from Stanford University.

Dr Michael Winlo, commented:

"I feel privileged to be joining dorsaVi and look forward to helping direct the company's growth strategy. As a leading provider of AI-enabled sensor technology, I believe dorsaVi is uniquely placed to capitalise on digitisation trends in the healthcare sector, as companies continue to focus on employee well-being. I am eager to contribute to dorsaVi's growth journey and commercial success and am excited by its future prospects."

Dr Michael Panaccio, dorsaVi's Acting Chairman, commented:

"We are delighted to welcome Dr Michael Winlo to the dorsaVi Board of Directors. Michael has extensive knowledge in the life sciences and technology sectors with a proven track record of commercial successes. We are excited to begin working with Michael and leveraging his extensive experience to improve our product offering, pursue new avenues for growth, develop strategic relationships and generate shareholder value."

– ENDS –

For further information about dorsaVi, please contact:

Company

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsavi.com

Investors

Dean Dribbin
Vesparum Capital
+61 3 8582 4800
Email: dorsavi@vesparum.com

This announcement was authorised for release by the Board of dorsaVi.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). dorsaVi's Telehealth provides a virtual clinic, enabling clinicians to do business differently and take their patient consultations online. Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com